Validity of an unsupervised self-administered questionnaire for self-assessment of melanoma risk

Melanoma Research

Volumn 13, Issue 5, 2003, Pages 537-542

  Harbauer, Alexandra ^a   Binder, Michael ^a   Pehamberger, Hubert ^a   Wolff, Klaus ^a   Kittler, Harald ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Melanoma; Risk factors; Screening; Self assessment

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; INTERVIEW; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MEDICAL ASSESSMENT; MELANOMA; PRIORITY JOURNAL; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SELF EVALUATION; STATISTICAL ANALYSIS;

CASE-CONTROL STUDIES; FEMALE; HUMANS; LIGHT; MALE; MELANOMA; MULTIVARIATE ANALYSIS; NEVUS; QUESTIONNAIRES; RISK; RISK FACTORS; ROC CURVE; SEX FACTORS; SKIN; SKIN NEOPLASMS; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 0142057349     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200310000-00013     Document Type: Article

References (28)

1. Garbe C, McLeod GR, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000; 89:1269-1278.
2. Johnson TM, Dolan OM, Hamilton TA, Lu MC, Swanson NA, Lowe L. Clinical and histologic trends of melanoma. J Am Acad Dermatol 1998; 38:681-686.
3. Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993; 71:3737-3743.
4. Buttner P, Garbe C, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995; 75:2499-2506.
5. Koh HK, Lew RA, Prout MN. Screening for melanoma/skin cancer: theoretic and practical considerations. J Am Acad Dermatol 1989; 20:159-172.
6. Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT. Screening for skin cancer. Am J Prev Med 2001; 20:47-58.
7. Wolfe JT. The role of screening in the management of skin cancer. Curr Opin Oncol 1999; 11:123-128.
8. Masri GD, Clark WH Jr, Guerry D IV, Halpern A, Thompson CJ, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990; 22:1042-1048.
9. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993; 341:1618-1620.
10. Gruber SB, Roush GC, Barnhill RL. Sensitivity and specificity of self-examination for cutaneous malignant melanoma risk factors. Am J Prev Med 1993; 9:50-54.
11. Little P, Keefe M, White J. Self screening for risk of melanoma: validity of self mole counting by patients in a single general practice. BMJ 1995; 310:912-916.
12. Melia J, Harland C, Moss S, Eiser JR, Pendry L. Feasibility of targeted early detection for melanoma: a population-based screening study. Br J Cancer 2000; 82:1605-1609.
13. Buettner PG, Garbe C. Agreement between self-assessment of melanocytic nevi by patients and dermatologic examination. Am J Epidemiol 2000; 151:72-77.
14. MacKie RM, Aitchison TC, Freudenberger T. Risk factors for melanoma. Lancet 1989; ii:928.
15. Jackson A, Wilkinson C, Ranger M, Pill R, August P. Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? A prospective study to validate a self administered risk score. BMJ 1998; 316:34-38.
16. Grulich AE, Bataille V, Swerdlow AJ, Newton-Bishop JA, Cuzick J, Hersey P, McCarthy WH. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer 1996; 67:485-491.
17. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JA, Clark J, Hole DJ. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ (Clin Res Ed) 1986; 292:1555-1559.
18. Chouinard N, Therrien JP, Mitchell DL, Robert M, Drouin R, Rouabhia M. Repeated exposures of human skin equivalent to low doses of ultraviolet-B radiation lead to changes in cellular functions and accumulation of cyclobutane pyrimidine dimers. Biochem Cell Biol 2001; 79:507-515.
19. Green A, Whiteman D, Frost C, Battistutta D. Sun exposure, skin cancers and related skin conditions. J Epidemiol 1999; 9:S7-13.
20. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124:869-871.
21. Autier P, Dore JF. Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer 1998; 77:533-537.
22. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73:198-203.
23. Cutler C, Foulkes WD, Brunet JS, Flanders TY, Shibata H, Narod SA. Cutaneous malignant melanoma in women is uncommonly associated with a family history of melanoma in first-degree relatives: a case-control study. Melanoma Res 1996; 6:435-440.
24. Ford D, Bliss JM, Swerdlow AJ, Armstrong BK, Franceschi S, Green A, et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62:377-381.
25. Kang S, Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994; 130:999-1001.
26. Halpern AC, Guerry D IV, Elder DE, Clark WH Jr, Synnestvedt M, Norman S, Ayerle R. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991; 127:995-999.
27. English DR, Armstrong BK. Identifying people at high risk of cutaneous malignant melanoma: results from a case-control study in Western Australia. BMJ (Clin Res Ed) 1988; 296:1285-1288.
28. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3:159-156.